ALK and non-small cell lung carcinoma: Riess et al. reported that chemotherapy containing pemetrexed and bevacizumab was effective in three patients with NSCLC and ocular metastasis positive for driver oncogenes (two patients with an EGFR mutation and one with an ALK fusion gene), although all of them received chemotherapy containing pemetrexed and bevacizumab as a first-line treatment [16].